Admilparant
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Admilparant
- Molecular weight
- 445.52
- Structure (SMILES)
- CCCN(C)C(=O)OCc1c(-c2ccc(O[C@H]3CCC[C@H](C(=O)O)C3)c(C)n2)nnn1C
- admilparant
- Admilparant
- admilparant [INN]
- ADMILPARANT [USAN]
- admilparant inn
- admilparant usan
- bms 986 278
- bms 986278
- BMS 986278
- BMS 986278 [WHO-DD]
- bms 986278 who dd
- BMS-986,278
- Bms-986278
- BMS-986278
- BMS-986278 suspension
- BMS-986278 Tablet
- bms986278
- BMS986278
- CAS registry numbers
- 2170126-74-4
- ChEMBL ID
- CHEMBL5087506
- InChIKey
- UEUNDURNLYLSNB-HOTGVXAUSA-N
- PubChem compound IDs
- 132232205
- FDA ingredient codes (UNII)
- 4UN9AOU6G8
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- Yes
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- BMS-986278
- Type
- Synthetic organic
Mechanisms of action
- Action
- Antagonist
- Action type
- Antagonist
- Target
- LPA1 receptor
- Gene symbol
- LPAR1
- Protein identifier
- Q92633
- Median affinity
- 8.16
- Affinity units
- pKB
- Condition
- Idiopathic Pulmonary Fibrosis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000768
- Subject identifier
- D054990
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001421
- Subject identifier
- D008107
- Condition
- Pulmonary Fibrosis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0009448
- Subject identifier
- D011658
- Condition
- Lung Diseases, Interstitial
- Highest recorded phase
- 1
- Condition identifier
- HP:0006515
- Subject identifier
- D017563
- Condition identifier
- EFO_0000768
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001421
- Highest recorded phase
- 1
- Condition identifier
- EFO_0009448
- Highest recorded phase
- 3
- Condition identifier
- HP_0006515
- Condition identifier
- MONDO_0002771
- Highest recorded phase
- 3
- NCT03981094
- NCT06003426
- NCT04308681
- NCT06025578
- NCT06425198
- Hydrogen bond acceptors
- 8
- Hydrogen bond donors
- 1
- Polar surface area
- 119.67
- Calculated partition coefficient (ALogP)
- 3.19
- Calculated partition coefficient (XLogP)
- 2.1
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 8
- Heavy atoms
- 32
- Molecular formula
- C22H31N5O5
- Monoisotopic mass
- 445.23251911
- Natural product
- No
- Recorded assays
- 70
- Active assays
- 4
Active assay types
- Confirmatory
Distribution coefficient (LogD)
- Median
- 1.95
- Mean
- 1.95
- Minimum
- 1.95
- Maximum
- 1.95
- Unit
- unitless
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- LogD
Solubility
- Median
- 4,601
- Mean
- 4,601
- Minimum
- 2,989
- Maximum
- 6,213
- Unit
- ug/mL
- Assays
- 2
- Standard deviation
- 2,279.71
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- Solubility
Oral bioavailability
- Median
- 79
- Mean
- 83
- Minimum
- 70
- Maximum
- 100
- Unit
- %
- Assays
- 3
- Standard deviation
- 15.3948
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (20)
- A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)
- A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis
- A Study of Experimental Medication BMS-986278 Given to Healthy Participants
- A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants
- A Study to Assess the Effect of Food on the Drug Levels of Admilparant
- A Study to Assess the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on BMS-986278 in Healthy Participants
- A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants
- A Study to Assess the Levels in Blood Plasma of BMS-986278 in Healthy Participants Following Administration of Tablets, With or Without Food, and in the Presence of an Antacid (Esomeprazole)
- A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis
- A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants
- A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986278 in Healthy Chinese Participants
- A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants
- A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
- A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
- A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants
- An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants
- Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
- Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment
- Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male Participants
In development for (4)
- Idiopathic pulmonary fibrosis Phase 3
- Interstitial lung disease Phase 1
- Liver disorder Phase 1
- Pulmonary fibrosis Phase 3